Recent epidemiologic studies have shown associations between ambient particle concentrations and changes in heart rate variability (HRV), a measure of autonomic function.  In panel studies of healthy senior citizens ([@b4-ehp0114-000560]; [@b5-ehp0114-000560]), cardiac patients ([@b7-ehp0114-000560]; [@b10-ehp0114-000560]), and healthy adult boilermakers ([@b8-ehp0114-000560]), airborne particles were associated with decreased HRV, a known risk factor for sudden death.  Conflicting results were found in a study of seniors with chronic obstructive pulmonary disease (COPD), which showed no associations between HRV and particulate matter \< 10 μ m aerodynamic diameter (PM~10~) and PM~2.5~ ([@b2-ehp0114-000560]), and in a study of healthy young highway patrolmen, which showed strong increases in HRV with PM~2.5~ exposures ([@b11-ehp0114-000560]).  Results from these studies suggest that compromised autonomic control of the heart may play a role in the acute cardiovascular toxicity of particles but that this role may differ with the underlying health status of the individual.  The impact of health status on the relationship between HRV and ambient PM, however, has not been examined directly, with panel studies conducted to date including participants of only one susceptible disease group.  To examine this issue more directly, we conducted a study to evaluate associations between ambient fine particles (PM~2.5~) and HRV for sensitive individuals and examine whether these associations differed for individuals with preexisting pulmonary disease compared with those with cardiovascular disease. 

Materials and Methods
=====================

In fall 1999 and spring 2000, repeated health and exposure measurements were made under a protocol approved by the Harvard School of Public Health Human Subjects Committee.  Measurements were made for individuals living in metropolitan Atlanta, Georgia, who had a myocardial infarction (MI) 3--12 months before the start of the study or had self-reported, physician-diagnosed moderate-to-severe COPD.  Each of these individuals provided informed consent to participate in the study.  Data for this analysis were collected as part of a more comprehensive investigation designed to examine the cardiovascular health effects of fine particles.  Measurements were made for each participant over 7 consecutive days in one or both seasons, with health measurements made each morning and exposure measurements made each day, beginning 24 hr before the health measurements.  Five participants were monitored simultaneously each 7-day period.  Twenty-four and 22 individuals participated in the fall and spring, respectively, with 13 individuals (6 with MI, 7 with COPD) participating in both seasons.  A total of 30 individuals (12 individuals with a recent MI and 18 individuals with COPD) participated in the study. 

Participant recruitment and baseline health assessment. 
-------------------------------------------------------

Participants were recruited from a number of locations in the metropolitan Atlanta area; the primary method for recruitment was through physician clinics and rehabilitation centers.  Once the individual had expressed interest in participating and his or her primary care physician had granted approval, several screening procedures were undertaken.  These included questionnaires on medical history, medication use, housing characteristics, and vitamin use; baseline spirometry; and a resting 12-lead electrocardiogram (ECG) (MAC6; Marquette Medical Systems Inc., Milwaukee, WI, USA).  Exclusion criteria were similar to those of the Boston, Massachusetts, HRV study conducted by [@b5-ehp0114-000560] and included unstable angina, atrial flutter, atrial fibrillation, paced rhythm, left bundle branch block, on constant oxygen, smoking or living with smokers, and inability to walk on level ground.  Two participants were unable to successfully complete the pulmonary function maneuver; as a result, baseline spirometry measurements were obtained for 28 of the 30 participants. 

Health monitoring. 
------------------

Field technicians visited participants in their homes between 0700 hr and 1100 hr on each monitoring day.  At the beginning of each visit, field technicians administered a questionnaire on health status, medication use, vitamin intake, housing characteristics, and activity patterns.  Field technicians subsequently placed a Holter monitor (SEER MC ambulatory digital analysis recorder; GE Medical Systems, Milwaukee, WI, USA) on each participant and led the participant through a standardized HRV protocol. 

The HRV protocol included continuous Holter monitoring using electrodes in a modified V5 and AVF position.  The participant also wore a blood oximeter throughout the protocol (N-20P Oximeter; Nellcor, CA, USA).  While wearing these devices, participants were asked to follow a standardized protocol ([@b5-ehp0114-000560]) in which they were asked to rest in the supine position for 5 min, stand for 5 min, walk outside for 5 min, rest in the supine position for 5 min, and finally to perform paced breathing (5 sec inhalation and 5 sec exhalation) for 20 inhalation and exhalation cycles of 5 sec while being coached by a technician.  The paced breathing portion of the protocol was designed to evaluate whether the effects of pollution on HRV were independent of respiratory rate, which might also be influenced by pollution levels, and to bring out vagal tone in the assessment of HRV.  This standardized protocol has been used in other studies specifically for the evaluation of HRV (Sullivan 2005).  During each of the 5-min protocol portions, respiratory rate was measured, followed by two blood pressure readings using an automated blood pressure machine (NIBP Vital Signs Monitor; Welch Allyn, Skaneateles Falls, NY, USA).  The blood pressure readings during the standing portion of the protocol were taken after 2 min of standing had elapsed.  After the outdoor exercise, the order of the blood pressure readings and respiratory rate was reversed. 

We analyzed the Holter tapes using a Marquette MARS Workstation (Marquette Medical Systems, Milwaukee, WI, USA), with a sampling rate of 125 samples/sec, which is standard for routine HRV analyses and is "satisfactory" under the HRV guidelines ([@b14-ehp0114-000560]).  All analyses were reviewed by a trained technician for noise and artifact.  Ectopic beats were excluded in these analyses, with a linearly interpolated QRS based on the prior beat's R-R interval and the subsequent beat's R-R interval inserted, as is standard.  Holter tapes were analyzed for several measures of HRV, including both time and frequency domain outcomes.  Time domain outcomes included the standard deviation of normal R-R intervals (SDNN), the square root of the mean of the sum of squares of differences between adjacent NN intervals (RMSSD), and the percentage of the absolute differences between successive normal R-R intervals that exceed 50 msec (PNN50).  Frequency domain variables included high-frequency power of 0.15--0.40 Hz (HF) and low-frequency power of 0.04--0.15 Hz (LF). 

A total of 300 Holter monitoring sessions were completed for 31 subjects, 28 of whom had five or more measurements.  Of the 300 observations, 25 observations were excluded because of onset of atrial fibrillation, three because of second-degree block, and three were unreadable.  One participant was subsequently excluded from all analyses because of atrial fibrillation.  Of the 300 valid Holter sessions, three sessions were missing portions of the overall protocol.  These sessions were not excluded from subsequent data analyses because results did not differ based on their inclusion in the model. 

Pollution measurements. 
-----------------------

Hourly pollution and meteorologic data were obtained from sites located within the metropolitan Atlanta area that were operated as part of other studies ([Figure 1](#f1-ehp0114-000560){ref-type="fig"}).  Hourly ambient PM~2.5~ concentrations were measured at the Yorkville, Fort McPherson, and Tucker stationary ambient monitoring (SAM) sites, which were operated as part of the Assessment of Spatial Aerosol Composition in Atlanta and Southeastern Aerosol Research and Characterization studies ([@b9-ehp0114-000560]).  Sites were located throughout the metropolitan Atlanta area and were characterized by a variety of land uses.  Tucker is classified as a suburban/commercial site, Yorkville as a rural site, and Fort McPherson as an urban site.  Hourly PM~2.5~ concentrations were measured at these sites using a tapered element oscillating microbalance with a Nafion dryer placed upstream of the inlet (R&P, Albany, NY, USA).  Hourly ozone concentrations were measured using methods approved by the U.S. Environmental Protection Agency ([@b15-ehp0114-000560]) at SAM sites located at Tucker, Yorkville, and South Dekalb, a suburban site, whereas hourly carbon monoxide, sulfur dioxide, and nitrogen dioxide concentrations were measured using U.S. EPA-approved methods ([@b15-ehp0114-000560]) at the Tucker and South Dekalb sites.  Black carbon (BC) concentrations were measured using aethalometers at the Jefferson St. SAM site located in downtown Atlanta in a mixed industrial and residential site that was operated as part of the Aerosol and Inhalation Epidemiological Study network.  Meteorologic data, including temperature and relative humidity, were also obtained from the Jefferson St. SAM site. 

Analyses were conducted using three exposure periods: the hour during the recorded HRV protocol and the 4- and 24-hr mean before the HRV protocol.  Calculated 4-and 24-hr mean exposures were considered valid when data for \> 3 hr or \> 18 hr (75% of the hours), respectively, were available.  Because participant homes and SAM sites were located throughout metropolitan Atlanta, the average concentration for the available SAM sites was used as the PM~2.5~ and gaseous exposure measure.  Exposure data were void if data were available from only one SAM site.  Under these criteria, 100%, 84%, 89%, 91%, and 95% of the observations were valid for 4-hr exposures to PM~2.5~, NO~2~, CO, SO~2~, and O~3~, respectively. 

Data analysis. 
--------------

We examined the association between ambient pollution and HRV (for the entire 35-min period) using linear mixed-effect models.  The HRV outcomes measured in the models were log transformed.  Models controlled for time, meteorologic, and subject-related variables, including random effects for subjects, and adjusting for body mass index (BMI), temperature, and relative humidity as continuous variables and sex, age, medication use, season, hour, and day of week as categorical variables.  Medication use was included as a categorical variable for four medication types: beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and bronchodilators (nonsteroidal long- and short-acting), with values based on whether the participant was or was not prescribed the medication.  Because the relationship between weather and the outcome variables was nonlinear, both temperature and relative humidity were modeled using natural spline functions with 3 degrees of freedom.  Models did not control for heart rate, which is inversely associated with HRV.  When heart rate was included in the model, model results were similar, although with slightly lower coefficients. 

To identify factors that modify the association between HRV and ambient pollution, parameters, including disease status, baseline pulmonary function, medication use, respiratory rate, air conditioning use, exercise during the protocol, BMI, age, and heart rate, were included separately in models.  Medication use was controlled for in these models, with the exception of models examining effect modification by medication use.  Because only individuals with COPD took bronchodilator medications, models that were stratified by disease status did not control for bronchodilator medications.  Analyses of pollution and HRV were conducted with data combined across seasons.  All statistical analyses were conducted using S-Plus (Insightful Corporation, Seattle, WA, USA).  Unless otherwise indicated, statistical significance was determined based on a *p*-value of 0.05. 

Results
=======

Participant profiles. 
---------------------

Measurements were obtained for 30 individuals, 12 with recent MIs (3--6 months post-MI) and 18 with self-reported, physician-diagnosed moderate-to-severe COPD.  In total, 265 observations were obtained over all participants, 159 for those with COPD and 106 for those with a recent MI.  Participants lived throughout metropolitan Atlanta ([Table 1](#t1-ehp0114-000560){ref-type="table"}).  As shown in [Table 1](#t1-ehp0114-000560){ref-type="table"}, the COPD participants were generally older, with a higher percentage of females compared with the MI cohort.  As would be expected, the COPD cohort had lower baseline lung function \[forced expiratory volume in 1 sec (FEV~1~)\].  Medication use differed by disease group, with bronchodilators taken only by individuals with COPD and beta-blockers taken by a higher fraction of individuals with a recent MI.  Fewer COPD participants were never-smokers. 

Ambient pollution concentrations. 
---------------------------------

Ambient pollution levels varied substantially across the monitoring period ([Table 2](#t2-ehp0114-000560){ref-type="table"}), with similar distributions for the fall and spring monitoring seasons.  Distributions of 1-hr (not shown) and 24-hr ambient pollution concentrations were comparable to corresponding 4-hr values.  Four-hour PM~2.5~ concentrations were significantly correlated with 4-hr NO~2~ (*r* = 0.44, *p* \< 0.001) and CO (*r* = 0.43, *p* \< 0.001) concentrations in both seasons, with correlations strongest in the fall for both pollutants.  In both seasons, 4-hr PM~2.5~ concentrations were also significantly correlated with corresponding elemental carbon (EC) levels (*r* = 0.51, *p* \< 0.001).  Correlations were also strong among 4-hr ambient EC, NO~2~, and CO concentrations (*r*~EC-NO2~ = 0.67, *p* \< 0.001; *r*~EC-CO~ = 0.59, *p* \< 0.001; *r*~NO2-CO~ = 0.46, *p* \< 0.001), likely because motor vehicles are the major source for these pollutants outdoors. 

For PM~2.5~, 4-hr mean concentrations were lowest at the rural Yorkville site (13.2 ± 7.6 μ g/m^3^) compared with the Tucker (21.9 ± 10.5 μ g/m^3^) and Fort McPherson (18.5 ± 9.1 μ g/m^3^) SAM sites.  Despite these differences, their concentrations were strongly correlated, with Spearman correlation coefficients \> 0.75 for comparisons among the SAM sites and \> 0.89 for comparisons of the individual site concentrations with the mean concentration across the sites.  Although mean 4-hr concentrations were comparable across sites, correlations among the sites' 4-hr NO~2~ concentrations were more moderate but remained significant, with a Spearman correlation coefficient for a comparison of Tucker and South Dekalb concentrations of 0.44 and coefficients for comparisons with the mean NO~2~ concentration across the two sites \> 0.72.  Four-hour mean O~3~ concentrations differed substantially across the sites, with mean levels highest at Yorkville (33.8 ± 12.6 ppb), followed by Tucker (14.5 ± 10.5 ppb) and South Dekalb (8.0 ± 9.2 ppb) sites.  Correlations among the sites were also weaker, primarily due to the low correlations observed for the rural Yorkville site (0.30 and 0.00 for Yorkville--Tucker and Yorkville--South Dekalb comparisons, respectively). 

For EC, because hourly ambient EC concentrations were measured only at the Jefferson St. SAM site, spatial variability was evaluated using 24-hr ambient EC concentrations measured at the Yorkville and Jefferson St. SAM sites.  The mean 24-hr concentration at Jefferson St. (1.81 ± 1.06 μ g/m^3^) was approximately twice that for YRK (0.77 ± 0.45 μ g/m^3^), which is consistent with the fact that Jefferson St. was located in an urban/suburban area and Yorkville was located in a rural area.  Despite these differences in mean levels, 24-hr EC concentrations at these sites were moderately correlated during the study period, with a significant Spearman correlation of 0.47. 

HRV outcomes. 
-------------

Several of the HRV outcomes varied significantly by disease group ([Table 3](#t3-ehp0114-000560){ref-type="table"}).  Individuals with COPD, for example, had significantly lower SDNN and LF values compared with individuals with a recent MI as determined using the Wilcoxon rank sum test (*p* = 0.012 and 0.0003, respectively).  Heart rate, a potential modifier of HRV, was lower in the MI group (*p* \< 0.0001), which may reflect beta-blocker use in the MI cohort.  For all other outcomes, comparable values were found across disease group. 

Association between PM~2.5~ and HRV. 
------------------------------------

The association between ambient PM~2.5~ and SDNN was positive for individuals with COPD, with associations strongest for the 4-hr moving average ([Table 4](#t4-ehp0114-000560){ref-type="table"}**)**.  For the 4-hr moving average, SDNN rose by 7.5% (95% CI, 1.5--13.9%) per interquartile range (IQR) increase in ambient PM~2.5~ (10.64 μ g/m3).  In comparison, opposing effects of ambient PM~2.5~ on HRV were found in individuals who were post-MI, resulting in no significant overall summary effect of ambient PM~2.5~ on HRV in the entire population for moving averages of 1-, 4-, or 24-hr ([Table 4](#t4-ehp0114-000560){ref-type="table"}).  When these analyses were performed using models that included an interaction term between PM~2.5~ and disease status, the disease group-specific effects of ambient PM~2.5~ on HRV were similar to those obtained from our stratified analyses, with a significant interaction term.  As shown in [Table 5](#t5-ehp0114-000560){ref-type="table"}, associations of PM~2.5~ and other HRV measures, RMSSD, PNN50, LF, HF, and LF:HF ratio, generally followed similar trends by disease status, with associations significant only for LF in individuals with COPD. 

Association between HRV and other pollutants. 
---------------------------------------------

Four-hour ambient NO~2~ concentrations were associated with changes in SDNN when analyses were stratified by disease status ([Table 6](#t6-ehp0114-000560){ref-type="table"}), with results exhibiting trends consistent with those for ambient PM~2.5~. Effect sizes for NO~2~ were similar to those observed for ambient PM~2.5~ for individuals with COPD and were larger and more precise than those observed for ambient PM~2.5~ for individuals with an MI.  An IQR increase in 4-hr NO~2~ concentrations (10.75 ppb) was associated with a 6.9% (95% CI, 0.1--14.2) increase in SDNN in individuals with COPD and a 13.9% (95% CI, --22.2 to --4.7) decrease in SDNN in persons with a recent MI.  For EC, trends consistent with those for ambient PM~2.5~ and NO~2~ were observed; however, associations were insignificant.  Ambient O~3~ concentrations were not associated with SDNN when data were examined for all subjects or were stratified by disease group ([Table 6](#t6-ehp0114-000560){ref-type="table"}). 

Effect modification by additional diagnosis-related end points. 
---------------------------------------------------------------

The effect of medication use, respiratory rate, baseline pulmonary function (as measured by FEV~1~), air conditioning use, exercise during HRV measurement, BMI, age, and heart rate on the association between 4-hr ambient pollution and overall SDNN was examined to determine whether these factors was responsible for the differences in response between the disease groups.  Of these, medication use and baseline FEV~1~ were found to be significant effect modifiers for 4-hr PM~2.5~ and NO~2~ concentrations, with results comparable for the two pollutants ([Table 7](#t7-ehp0114-000560){ref-type="table"}).  Similar effect modification by medication use and baseline pulmonary function was also found for EC but with smaller effect sizes. 

Baseline FEV~1~.
----------------

Consistent with the results by disease group, baseline FEV~1~ (percent predicted) significantly modified the association between SDNN and 4-hr ambient PM~2.5~ and NO~2~ among all participants, with the PM~2.5~--SDNN association increasing with decreasing baseline FEV~1~. Coefficients for the main pollution effect and the FEV~1~ interaction term equaled 0.015 ± 0.004 (mean ± SE; *t*-value = 3.46) and --0.0002 ± 0.0001 (*t*-value = --3.18), respectively.  For individuals with poor pulmonary function (baseline FEV~1~ 35% of predicted; 10th percentile for study population), these values corresponded to a 10.2% increase in SDNN for an IQR increase in 4-hr ambient PM~2.5~ concentrations, whereas for individuals with normal pulmonary function (baseline FEV~1~ 105% of predicted; 90th percentile for the study population), these values corresponded to a 2.5% decrease in SDNN for the same IQR increase in PM~2.5~ ([Table 7](#t7-ehp0114-000560){ref-type="table"}). 

Medication use. 
---------------

Beta-blocker and bronchodilator use on the health measurement day significantly modified the association between 4-hr ambient PM~2.5~ and NO~2~ concentrations and SDNN ([Figure 2](#f2-ehp0114-000560){ref-type="fig"}).  SDNN decreased by 7.3% (95% CI, --13.8 to --0.35) for subjects taking beta-blockers and increased by 5.8% (95% CI, 0.91--10.8) for other subjects with an IQR increase in 4-hr ambient PM~2.5~. Responses were consistent in direction with those for individuals with an MI and COPD, respectively.  Opposite patterns were observed for subjects taking bronchodilator medications, where positive SDNN--PM~2.5~ associations were found for those on the medication and negative associations were found for other subjects.  The effect sizes for PM~2.5~-associated changes in SDNN for individuals taking medications were higher in magnitude compared with effect sizes for corresponding individuals with MI or COPD alone.  Medications that were taken by individuals from both disease groups, including ACE inhibitors and calcium channel blockers, were not found to modify the SDNN--PM~2.5~ association significantly. 

Effect of spatial variability on effect estimates. 
--------------------------------------------------

The effect of spatial variability in ambient PM~2.5~ on observed associations between overall SDNN and ambient PM~2.5~ and ambient NO~2~ was analyzed using data from each of the individual SAM sites.  For PM~2.5~, spatial variability in ambient concentrations had little effect on the observed associations because both the magnitude and direction of the association between SDNN and 4-hr ambient PM~2.5~ were comparable across sites ([Table 8](#t8-ehp0114-000560){ref-type="table"}**)**.  These results are consistent with the strong correlations among the sites' PM~2.5~ concentrations, with Spearman correlation coefficients \> 0.87 for pairwise comparisons of the 4-hr concentrations at the individual sites with the 4-hr across-site mean concentrations.  Results suggest that, for PM~2.5~, the mean ambient SAM PM~2.5~ concentration is a good indicator of ambient PM~2.5~ across the metropolitan Atlanta area. 

For NO~2~, we found similar trends by disease status when associations were estimated using data for the individual SAM sites compared with the mean of these sites ([Table 8](#t8-ehp0114-000560){ref-type="table"}).  The magnitude and significance of the associations, however, dropped, with associations for individuals with MIs no longer significant when measurements at the South DeKalb site were used in the analysis.  These findings suggest greater exposure error when measurements from single SAM sites were used to reflect exposures for our study population. 

Discussion
==========

Findings from our study provide direct evidence of heterogeneity in the autonomic response to ambient pollution that is dependent on the underlying health status of the study population.  Changes in HRV were significantly and positively associated with ambient PM~2.5~ concentrations for individuals with COPD.  Although not statistically significant, observed associations were consistently negative for individuals with recent MI.  Further support that the HRV response to ambient PM~2.5~ differs for individuals with MI and COPD was provided by the fact that we found comparable effect estimates, with significant differences between disease groups, using models that included an interaction term between pollution and disease status.  Associations with ambient PM~2.5~ were strongest for the 4-hr moving average and for SDNN, an overall measure of HRV, although consistent trends with disease status were observed for other moving averages and other HRV measures, including RMSSD, HF, and the LF:HF ratio.  We also observed strong and significant associations with SDNN by disease group with ambient NO~2~, and to a lesser extent with ambient EC.  Because ambient NO~2~ and EC originate primarily from motor vehicles, our findings suggest that motor vehicle-related pollution may be partly responsible for the observed effects of ambient particles on HRV. 

Because results were similar irrespective of whether models controlled for heart rate and because heart rate did not modify the PM~2.5~--HRV association, results suggest that the observed effect modification by disease status was due to factors other than differences in heart rate.  For individuals with recent MI, the negative, albeit insignificant, association observed between ambient PM~2.5~ and HRV was consistent with previous studies of elderly individuals ([@b4-ehp0114-000560]; [@b5-ehp0114-000560]), elderly individuals with preexisting cardiovascular-related conditions ([@b7-ehp0114-000560]), and occupationally exposed, middle-aged boilermakers (Magari et al.  2002). 

In contrast, our finding of positive associations between PM~2.5~ and HRV for individuals with COPD is in direct contrast to findings from the only other published study of pollution effects on HRV in individuals with COPD ([@b2-ehp0114-000560]), in which HRV was measured repeatedly for 16 individuals with mild-to-moderate COPD (FEV~1~ ≥ 0.75 L) living in Vancouver, British Columbia, Canada.  For these individuals, nonsignificant ambient PM~2.5~-associated decrements in SDNN and RMSSD were found, with the lack of statistical significance attributed to low ambient pollution levels and the small sample size.  The negative direction of the PM~2.5~--HRV association in Vancouver was comparable in magnitude to that observed in elderly individuals living in Boston ([@b5-ehp0114-000560]).  The contrasting PM~2.5~ and HRV associations for the Vancouver ([@b2-ehp0114-000560]) and our COPD cohorts may result from the fact that the Vancouver cohort had less severe pulmonary disease compared with our cohort (as defined by the self-reported physician diagnoses).  Positive associations between HRV and PM~2.5~ have been demonstrated previously in a study of a young, healthy cohort of highway patrolmen (Riedeker et al.  2004).  For these healthy patrolmen, SDNN increased significantly by 11.7% per 10 μ g/m^3^ in PM~2.5~ exposures.  This increase is comparable to our 7.5% increase for a similar change in ambient PM~2.5~ (10.64 μ g/m3).  Positive associations for the patrolmen were attributed to increased vagal activity in the young and healthy cohort. 

Cardiovascular autonomic neuropathy is common, although not universal, in patients with COPD ([@b3-ehp0114-000560]).  Although many patients with COPD have marked baseline sympathetic activation (Heindl 2001), individuals with COPD have been demonstrated to respond to stimuli such as exercise with increased vagal tone as measured by increases in HF ([@b1-ehp0114-000560]).  It is possible that ambient pollution has similar effects on increases in vagal tone among at least some subsets of patients with COPD. 

Because our COPD participants were generally older and less active than our MI participants, it is difficult to determine whether the observed effect modification by disease group reflect differences in the participant characteristics or in the diseases themselves.  Of the patient characteristics, medication use was an important modifier of the HRV--PM~2.5~ associations.  Individuals with COPD and MI were generally prescribed different medications, with beta-blocker and bronchodilator use limited largely to individuals with a recent MI and COPD, respectively.  Correspondingly, effect estimates for subjects taking beta-blockers exhibited similar trends as those for subjects with an MI, whereas effect estimates for subjects taking bronchodilators were consistent with those for individuals with COPD.  As a result of this strong overlap between medication use and disease group, it is not possible to separate the effects of medication use from disease in this study. 

Baseline pulmonary function, as measured using baseline FEV~1~, was also found to modify the association between ambient PM~2.5~ and SDNN.  From our linear model estimating the modification of PM~2.5~ effects by level of FEV~1~, we estimate that the PM~2.5~--HRV association decreased significantly with increasing pulmonary function, comparable to a 10.2% increase in SDNN for an IQR change in ambient PM~2.5~ for individuals with poor pulmonary function (baseline FEV~1~ 35% of predicted) and a 2.5% decrease in SDNN for individuals with normal lung function (baseline FEV~1~ 105% of predicted).  Because the baseline pulmonary function was normal and narrowly distributed for individuals with recent MI, the observed impact of baseline pulmonary function on the PM~2.5~--SDNN response largely reflects variation in baseline pulmonary function among individuals with COPD.  Because the influence of baseline pulmonary function on HRV was not examined in previous studies, it is unknown whether baseline pulmonary function had similar impacts on the PM-associated HRV response in the previously reported studies.  Evidence from cardiovascular health studies, however, suggests that respiratory health status may be an important modifier of the pollution-mediated autonomic response, because HRV in individuals with COPD has also been shown to decrease with FEV~1~ ([@b12-ehp0114-000560]).  Negative associations between average HRV and baseline FEV~1~, however, were not observed in our COPD cohort. 

Results for PM~2.5~ were robust with respect to location of the SAM site because results were comparable when PM~2.5~ concentrations at individual SAM sites were used as the exposure measure, suggesting that spatial variation in PM~2.5~ was not a significant source of exposure error for our study participants.  For NO~2~, similar sensitivity results show consistent trends in the NO~2~--HRV associations by disease group.  Larger differences in the effect estimates, however, were found with different methods to estimate ambient NO~2~ exposures, suggesting that exposure error due to spatial variability was greater for NO~2~ compared with PM~2.5~. This greater exposure error is consistent with the fact that traffic, which varies spatially over short distances, is a significant source of outdoor NO~2~. Although comparable sensitivity analyses could not be conducted for BC, significant correlations between 24-hr concentrations measured at the Jefferson St. and Yorkville sites suggest that BC concentrations measured at the Jefferson St. SAM site were able to reflect BC concentrations across Atlanta.  Because these correlations were more moderate compared with those for PM~2.5~ and were similar in magnitude to those for NO~2~, it is likely that spatial variation in outdoor BC levels contributed to error in our exposure estimates and thus may have affected our observed effect estimates.  For both NO~2~ and BC, this greater exposure error may explain the lower and insignificant effect estimates found for these pollutants. 

One important limitation of this investigation is the small number of individuals studied, with only 18 and 12 individuals with COPD and a recent MI, respectively.  Our findings of effect modification by medication use and baseline pulmonary function, COPD, and a recent MI, however, were consistent with our findings of differential susceptibility for individuals with COPD and a recent MI.  Further study is needed to identify factors responsible for this differential susceptibility and to identify whether the autonomic response of individuals with other health conditions also differ after ambient pollution exposures. 

C[orrection]{.smallcaps}
========================

The affiliation for D.R.G. was incorrect in the manuscript published online.  It has been corrected here. 

We thank E. Edgerton for help with the ambient monitoring data; F. Speizer, P. Koutrakis, and B. Ryan for their scientific input; and M. Davey, the field staff, and the study participants for assistance. 

This work was funded by the National Institute of Environmental Health Sciences (grants ES09825 and ES00002), the U.S. Environmental Protection Agency (grant R827353), the Electric Power Research Institute (grant WO7356-01), and the American Petroleum Institute. 

![ Locations of participants' homes and the SAM sites, Atlanta, Georgia.\
Abbreviations: FT, Fort McPherson; JST, Jefferson St.; SDe, South Dekalb; TU, Tuckerville; YRK, Yorkville.](ehp0114-000560f1){#f1-ehp0114-000560}

![ Percent change in SDNN with 4-hr PM~2.5~ (*A*) and NO~2~ (*B*), expressed with 95% CI per IQR change in PM~2.5~ (10.64 μ g/m^3^) or NO~2~ (10.75 ppb).  Medication use status is based on whether participant took medication on the morning of the health measurement.  All percent changes differed significantly by medication use at *p =* 0.05.](ehp0114-000560f2){#f2-ehp0114-000560}

###### 

Participant characteristics by disease status. 

                                                                                                                       Disease group                  
  -------------------------------------------------------------------------------------------------------------------- --------------- -------------- -------------
  Sex[b](#tfn2-ehp0114-000560){ref-type="table-fn"}                                                                                                   
   Male                                                                                                                7               10             30
   Female                                                                                                              11              2              
  Age (years)[c](#tfn3-ehp0114-000560){ref-type="table-fn"}                                                                                           
   Male                                                                                                                74 (71--76)     59 (49--70)    65 (55--73)
   Female                                                                                                              64 (49--75)     69 (66--71)    
  FEV~1~ (% predicted) [c](#tfn3-ehp0114-000560){ref-type="table-fn"},[d](#tfn4-ehp0114-000560){ref-type="table-fn"}                                  
   Male                                                                                                                67 (43--80)     99 (86--115)   69 (44--98)
   Female                                                                                                              45 (36--59)     96 (91--101)   
  BMI[c](#tfn3-ehp0114-000560){ref-type="table-fn"}                                                                    27 (22--31)     27 (25--28)    27 (25--29)
  Medication use[a](#tfn1-ehp0114-000560){ref-type="table-fn"}                                                                                        
   Beta-blockers                                                                                                       1               8              9
   Calcium channel blockers                                                                                            4               3              7
   ACE inhibitors                                                                                                      3               6              9
   Bronchodilators, short acting[e](#tfn5-ehp0114-000560){ref-type="table-fn"}                                         12              0              12
   Bronchodilator, long acting[f](#tfn6-ehp0114-000560){ref-type="table-fn"}                                           5               0              5

Totals for all participants. 

Expressed as number of participants. 

Expressed as mean (interquartile range). 

Does not include data for two participants, for which baseline pulmonary function could not be measured. 

Albuterol, salmeterol, pirbuterol, ipratropium bromide and albuterol, and ipratropium bromide. 

Theophylline. 

###### 

Summary of meteorologic and air pollution levels. 

                                         Percentile                                   
  ------------------------ ----- ------- ------------ ------- ------- ------- ------- -------
  Meteorology (24 hr)                                                                 
   Temperature (°C)        265   17.8    12.2         16.1    18.0    20.3    23.6    ---
   Relative humidity (%)   265   70.3    52.5         57.4    70.1    82.6    92.6    ---
  Pollution (4 hr)                                                                    
   PM~2.5~ (μ g/m^3^)      264   17.8    7.0          11.6    16.5    22.2    30.9    17.2
   EC (μ g/m^3^)           260   2.3     0.9          1.2     1.6     2.9     4.4     2.0
   O~3~ (ppb)              251   18.5    9.0          12.7    17.0    22.5    30.3    29.4
   CO (ppb)                236   362.0   169.7        221.5   304.3   398.1   682.1   332.1
   SO~2~ (ppb)             240   1.9     0.7          0.9     1.5     2.4     3.6     2.5
   NO~2~ (ppb)             222   17.8    7.1          12.0    17.0    22.8    29.8    17.1

Values correspond to the mean for the 24-hr or 4-hr periods before the HRV measurements. 

Corresponding 24-hr mean values for time period before the health measurements. 

###### 

HRV \[mean (10th percentile, 90th percentile)\] by disease status.[a](#tfn9-ehp0114-000560){ref-type="table-fn"}

  HRV parameter      COPD (*n* = 18)        MI (*n* = 12)
  ------------------ ---------------------- -----------------------
  SDNN (msec)        104.4 (55.2, 186.2)    114.8 (63.8, 207.4)
  RMSSD (msec)       44.5 (14.4, 129.4)     39.2 (12.6, 115.2)
  PNN50 (%)          10.0 (0.4, 30.9)       6.4 (0.2, 23.2)
  LF (msec^2^)       759.1 (62.8, 3700.6)   808.1 (115.5, 2726.2)
  HF (msec^2^)       333.4 (36.1, 1278.1)   361.0 (49.8, 1356.9)
  LF:HF ratio        2.5 (1.1, 6.8)         3.7 (0.9, 7.4)
  Heart rate (bpm)   80.9 (64.2, 105.7)     68.6 (54.0, 86.7)

Includes data for all participants in both seasons; means and 10th and 90th percentiles expressed as the values for the participant means. 

###### 

Association between ambient PM~2.5~ and overall SDNN. 

  PM~2.5~ integration period   IQR (μ g/m^3^)   Percent change                                         95% CI
  ---------------------------- ---------------- ------------------------------------------------------ ---------------------------------------------------------------
  1 hr                         10.3             1.50                                                   --2.22 to 5.36
   MI only                     9.74             --2.75                                                 --7.93 to 2.72
   COPD only                   10.66            5.07[\*](#tfn11-ehp0114-000560){ref-type="table-fn"}   0.01 to 10.38[\*](#tfn11-ehp0114-000560){ref-type="table-fn"}
  4 hr                         10.63            1.97                                                   --2.30 to 6.43
   MI only                     8.54             --2.89                                                 --7.79 to 2.27
   COPD only                   11.65            8.29[\*](#tfn11-ehp0114-000560){ref-type="table-fn"}   1.71 to 15.30[\*](#tfn11-ehp0114-000560){ref-type="table-fn"}
  24 hr                        8.00             --1.00                                                 --4.67 to 2.82
   MI only                     8.05             --4.38                                                 --9.42 to 0.94
   COPD only                   7.84             1.58                                                   --3.59 to 7.01

Percent change in overall SDNN (with 95% CIs) expressed per IQR change in ambient PM~2.5~. Model does not include heart rate. 

Statistically significant estimate. 

###### 

Association between ambient 4-hr PM~2.5~ and other HRV parameters. 

  HRV measure   Percent change                                          95% CI             *t*-Value
  ------------- ------------------------------------------------------- ------------------ -----------
  SDNN          1.97                                                    --2.30 to 6.43     0.90
   MI           --2.89                                                  1.71 to 2.27       --1.11
   COPD         8.29[\*](#tfn13-ehp0114-000560){ref-type="table-fn"}    --7.79 to 15.30    2.49
  RMSSD         --0.92                                                  --10.19 to 9.30    --0.18
   MI           --11.38                                                 --23.03 to 2.03    --1.68
   COPD         9.77                                                    --5.37 to 27.35    1.23
  PNN50         --2.96                                                  --18.15 to 15.03   --0.35
   MI           --10.18                                                 --29.94 to 15.17   --0.85
   COPD         --1.19                                                  --21.07 to 23.70   0.10
  LF            14.04                                                   --1.84 to 32.49    1.72
   MI           1.12                                                    --15.52 to 21.03   0.12
   COPD         35.88[\*](#tfn13-ehp0114-000560){ref-type="table-fn"}   6.79 to 72.90      2.49
  HF            5.03                                                    --9.96 to 22.52    0.62
   MI           --6.48                                                  --25.68 to 17.70   --0.57
   COPD         19.41                                                   --4.05 to 48.59    1.59
  LF:HF ratio   1.85                                                    --4.91 to 9.09     0.52
   MI           --1.28                                                  --9.16 to 7.28     --0.30
   COPD         6.68                                                    --4.02 to 18.59    1.20

Data are percent change in HRV (overall protocol) expressed per IQR change in 4-hr ambient PM~2.5.~ IQR changes were 10.6, 8.5, and 11.7 μ g/m^3^ for the 4-hr mean of the SAM sites for all, MI, and COPD participants, respectively.  Model does not include heart rate. 

Statistically significant estimate. 

###### 

Association between 4-hr EC, NO~2~, and O~3~ concentrations and overall SDNN. 

  Pollutant    IQR     Percent change                                            95% CI
  ------------ ------- --------------------------------------------------------- -----------------
  EC           1.68    --0.83                                                    --3.27 to 1.67
   MI only     1.39    --1.06                                                    --4.19 to 2.16
   COPD only   1.92    0.51                                                      --3.33 to 4.51
  NO~2~        10.66   --0.49                                                    --5.4 to 4.6
   MI only     9.25    --12.09[\*](#tfn15-ehp0114-000560){ref-type="table-fn"}   --19.5 to --4.0
   COPD only   11.97   7.70[\*](#tfn15-ehp0114-000560){ref-type="table-fn"}      0.1 to 15.9
  O~3~         9.61    0.75                                                      --3.6 to 5.3
   MI only     8.08    0.13                                                      --6.5 to 7.2
   COPD only   10.66   2.45                                                      --3.4 to 8.7

Data are percent change in overall SDNN (with 95% CIs) expressed per IQR change in pollutant concentrations.  Units for IQR are μ g/m^3^ for EC, and ppb for O~3~ and NO~2~. Model does not include heart rate. 

Statistically significant estimate. 

###### 

Association of SDNN and ambient 4-hr concentrations: baseline FEV~1~ (percent predicted) as an effect modifier. 

  Pollutant                 FEV~1~   Percent change                                          95% CI[a](#tfn16-ehp0114-000560){ref-type="table-fn"}
  ------------------------- -------- ------------------------------------------------------- -------------------------------------------------------
  PM~2.5~ (10.6 μ g/m^3^)   105      --2.5                                                   --7.8 to 3.2
                            35       10.2[\*](#tfn17-ehp0114-000560){ref-type="table-fn"}    3.8 to 17.0
  EC (1.7 μ g/m^3^)         105      --3.9[\*](#tfn17-ehp0114-000560){ref-type="table-fn"}   --7.4 to --0.3
                            35       2.5                                                     --1.3 to 6.4
  NO~2~ (10.7 ppb)          105      --5.4                                                   --12.0 to 1.8
                            35       5.7                                                     --1.2 to 12.9
  O~3~ (9.6 ppb)            105      --0.4                                                   --7.1 to 6.8
                            35       1.1                                                     --4.1 to 6.6

Expressed as a change per IQR for the 4-hr mean ambient concentration. 

Statistically significant association. 

###### 

Association between ambient 4-hr PM~2.5~ and SDNN by SAM site. 

  Pollutant/SAM site   IQR     Percent change                                            95% CI            *t*-Value
  -------------------- ------- --------------------------------------------------------- ----------------- -----------
  PM~2.5~                                                                                                  
   Mean of SAM sites   10.63   1.97                                                      --2.30 to 6.43    0.90
    MI                 8.54    --2.89                                                    --7.79 to 2.27    --1.11
    COPD               11.65   8.29[\*](#tfn19-ehp0114-000560){ref-type="table-fn"}      1.71 to 15.30     2.49
   Tucker              15.40   1.74                                                      --3.2 to 6.9      0.68
    MI                 14.33   --3.59                                                    --10.3 to 3.6     --1.00
    COPD               15.98   7.39[\*](#tfn19-ehp0114-000560){ref-type="table-fn"}      0.4 to 14.9       2.07
   Fort McPherson      13.04   1.13                                                      --3.7 to 6.2      0.45
    MI                 12.68   --5.35                                                    --11.7 to 1.5     --1.55
    COPD               13.78   7.10                                                      0.05 to 14.7      1.97
   Yorkville           8.35    2.71                                                      --1.3 to 6.9      1.31
    MI                 7.99    --3.63                                                    --9.0 to 2.0      --1.27
    COPD               8.52    8.23[\*](#tfn19-ehp0114-000560){ref-type="table-fn"}      2.2 to 14.6       2.72
  NO~2~                                                                                                    
   Mean of SAM sites   10.66   --0.49                                                    --5.4 to 4.7      --0.19
    MI                 9.25    --13.88[\*](#tfn19-ehp0114-000560){ref-type="table-fn"}   --22.1 to --4.7   --2.88
    COPD               11.97   6.89[\*](#tfn19-ehp0114-000560){ref-type="table-fn"}      0.1 to 14.2       1.97
   Tucker              13.75   --1.61                                                    --5.9 to 2.9      --0.71
    MI                 12.88   --10.36[\*](#tfn19-ehp0114-000560){ref-type="table-fn"}   --17.7 to --2.4   --2.53
    COPD               13.75   3.75                                                      --2.1 to 10.0     1.24
   South Dekalb        12.06   0.57                                                      --4.7 to 6.1      0.21
     MI                11.06   --6.50                                                    --14.6 to 2.4     --1.45
    COPD               12.19   4.99                                                      --1.7 to 12.2     1.44

Data are percent change in overall SDNN expressed per IQR change in ambient PM~2.5~. Model does not include heart rate. 

Statistically significant estimate. 

[^1]: The authors declare they have no competing financial interests.